Endothelin as a final common pathway in the pathophysiology of preeclampsia
- 1 March 2012
- journal article
- pathophysiology of-hypertension
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Nephrology and Hypertension
- Vol. 21 (2), 157-162
- https://doi.org/10.1097/mnh.0b013e328350094b
Abstract
Purpose of review Preeclampsia remains a major health concern in the United States and worldwide. Recent research has begun to shed light on the underlying mechanisms responsible for the symptoms of preeclampsia, and may provide new avenues for therapy for the preeclamptic patient. Recent findings The central role of placental ischemia in the manifestation of preeclampsia has provided new understanding for the origin of pathogenic factors in the preeclamptic patient. The release of soluble factors into the maternal bloodstream from the ischemic placenta is now recognized as a central mechanism in disease manifestation. Specifically, the importance of the vascular endothelial growth factor antagonist soluble fms-like tyrosine kinase and immune factors as factors regulating maternal endothelial dysfunction has become widely acknowledged. Furthermore, mounting evidence implicates the signaling protein endothelin-1 as the final converging factor in the multifaceted cascades that are responsible for the symptomatic manifestation of preeclampsia. Endothelin-1, as a final common pathway in the pathogenic cascade of preeclampsia, presents an intriguing new therapeutic approach for preeclamptic patients. Summary Identification of antiangiogenic, autoimmune, and inflammatory factors produced in response to placental ischemia have provided potential new avenues for future research into novel therapies for the preeclamptic patient, and suggest new therapeutic avenues for the treatment of preeclampsia.Keywords
This publication has 46 references indexed in Scilit:
- Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signallingCardiovascular Research, 2010
- A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic useJournal of Cellular and Molecular Medicine, 2010
- Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With PlacentalIschemia-Induced HypertensionHypertension, 2010
- Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant RatsHypertension, 2010
- Hypertension in Response to Autoantibodies to the Angiotensin II Type I Receptor (AT1-AA) in Pregnant RatsHypertension, 2009
- Oxidative Stress Contributes to Soluble Fms-Like Tyrosine Kinase-1 Induced Vascular Dysfunction in Pregnant RatsAmerican Journal of Hypertension, 2009
- Hypertension in Response to Chronic Reductions in Uterine Perfusion in Pregnant RatsHypertension, 2008
- Autoantibodies to the Angiotensin Type I Receptor in Response to Placental Ischemia and Tumor Necrosis Factor α in Pregnant RatsHypertension, 2008
- Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant miceNature Medicine, 2008
- Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells SignalingHypertension, 2008